Dehydrogenase Inhibitors

Catalog No.	Product Name	Information
E8291	ABD0171	ABD0171 is a potent, irreversible, and selective inhibitor of aldehyde dehydrogenase 1A3 (ALDH1A3), with an IC50 of 0.34 µM using the physiological substrate all-trans-retinaldehyde (atRAL). It also inhibits ALDH1A2 and ALDH1A1 with IC50 of 0.79 µM and 6.6 µM, respectively. ABD0171 disrupts key oncogenic pathways in triple-negative breast cancer (TNBC) cells in vitro and exhibits robust antitumor and antimetastatic activity in vivo.
E5800	G6PD activator AG1	G6PD activator AG1 is a small molecule activator of glucose-6-phosphate dehydrogenase (G6PDH) with an EC50 of 3.4 µM for G6PDH⁴⁵⁹ᴸ that enhances the activity of wild-type and mutant G6PD. It reduces oxidative stress in cells, zebrafish, and human erythrocytes, making it useful for research on G6PD enzymopathies.
E5843	PDK4-IN-1 hydrochloride	PDK4-IN-1 hydrochloride is an anthraquinone-derived, orally active allosteric inhibitor of PDK4 with an IC50 of 84 nM, exhibiting anticancer activity by regulating cell proliferation, transformation, and apoptosis. It also exhibit antidiabeti and anti-allergic activity.
E5804	Gliocidin	Gliocidin (SW106065), is a nicotinamide-mimetic prodrug that targets glioblastoma cells with an IC50 of 150 nM, by exploiting a de novo purine synthesis vulnerability via indirect inhibition of IMPDH2. It readily crosses the BBB and can be used in the treatment of all malignant brain tumors.
E8199	GNE-140 racemate	GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140 and a potent and specific inhibitor of Lactate dehydrogenase A(LDH-A). It reduces breast cancer cell proliferation, motility, and invasion, making it a potential candidate for cancer research.
≡ All Dehydrogenase Inhibitors

New Dehydrogenase Inhibitors